Full-Time

Data Privacy and Policy Lead

Posted on 7/17/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Expert

Hyderabad, Telangana, India

In Person

Category
Cybersecurity
IT & Security
Requirements
  • Technical data management skills with in-depth knowledge of Pharma data regulations.
  • Aware of industry trends and priorities and can apply to governance and policies.
  • In-depth knowledge and experience with data masking, data access controls, and technologies to enable a scalable operating model.
  • Experience with data products development life cycle, including the enablement of data dictionaries, business glossary to increase data products reusability and data literacy.
Responsibilities
  • Responsible for co-developing frameworks, in partnership with Enterprise Data Management Platforms team, to enable technology to discover, tag, and generate metadata to manage data access controls.
  • Manage a team of Data Governance Specialists and Data Stewards– directly or in a matrix organization structure.
  • Responsible for operationalizing the data access controls and in partnership with functional data owners and technology teams, ensure data access controls, compliance with privacy and security regulations are enforced.
  • Maintain policies and ensures compliance with data privacy, security, and regulatory policies.
  • Publish metrics to measure effectiveness and drive adoption of Data Access policies and standards, that will be applied to mitigate identified risks across the data lifecycle (e.g., capture / production, aggregation / processing, sharing, reporting / consumption).
Desired Qualifications
  • Experience managing industry external data assets (e.g. Claims, EHR, etc.)
  • Ability to successfully execute complex projects in a fast-paced environment and in managing multiple priorities effectively.
  • Ability to manage projects or departmental budgets.
  • Experience with modelling tools (e.g., Visio).
  • Basic programming skills, experience in data visualization and data modeling tools.
  • Experience working with agile development methodologies such as Scaled Agile.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.